ATE525484T1 - Slco1b3-genotyp - Google Patents

Slco1b3-genotyp

Info

Publication number
ATE525484T1
ATE525484T1 AT08713083T AT08713083T ATE525484T1 AT E525484 T1 ATE525484 T1 AT E525484T1 AT 08713083 T AT08713083 T AT 08713083T AT 08713083 T AT08713083 T AT 08713083T AT E525484 T1 ATE525484 T1 AT E525484T1
Authority
AT
Austria
Prior art keywords
methods
determining
prostate cancer
differences
slco1b3
Prior art date
Application number
AT08713083T
Other languages
English (en)
Inventor
William Figg
Alex Sparreboom
Akinobu Hamada
Douglas Price
Tristan M Sissung
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE525484T1 publication Critical patent/ATE525484T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT08713083T 2007-01-08 2008-01-08 Slco1b3-genotyp ATE525484T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87950307P 2007-01-08 2007-01-08
PCT/US2008/000310 WO2008086002A2 (en) 2007-01-08 2008-01-08 Slco1b3 genotype

Publications (1)

Publication Number Publication Date
ATE525484T1 true ATE525484T1 (de) 2011-10-15

Family

ID=39609290

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08713083T ATE525484T1 (de) 2007-01-08 2008-01-08 Slco1b3-genotyp

Country Status (6)

Country Link
US (1) US10094836B2 (de)
EP (1) EP2115173B1 (de)
AT (1) ATE525484T1 (de)
AU (1) AU2008205330B2 (de)
CA (1) CA2674788A1 (de)
WO (1) WO2008086002A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ572036A (en) 2008-10-15 2010-03-26 Nikola Kirilov Kasabov Data analysis and predictive systems and related methodologies
US10273544B2 (en) 2010-02-11 2019-04-30 Dana-Farber Cancer Institute, Inc. Methods for predicting likelihood of responding to treatment
WO2012033918A2 (en) * 2010-09-08 2012-03-15 Mayo Foundation For Medical Education And Research Predicting responses to androgen deprivation therapy
CN102952872B (zh) * 2011-08-29 2014-06-18 益善生物技术股份有限公司 一种slco1b3基因多态性检测特异性引物和液相芯片
WO2015009603A1 (en) 2013-07-15 2015-01-22 The Cleveland Clinic Foundation 3b -hydroxysteroid dehydrogenase in steroid-dependent disease
US10395759B2 (en) 2015-05-18 2019-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for copy number variant detection
AU2017218149B2 (en) 2016-02-12 2020-09-03 Regeneron Pharmaceuticals, Inc. Methods and systems for detection of abnormal karyotypes
WO2018038943A1 (en) * 2016-08-11 2018-03-01 Siemens Healthcare Diagnostics Inc. Heating device for a filtration assembly
CN112415206B (zh) * 2020-10-23 2023-08-18 上海良润生物医药科技有限公司 外泌体中的cd171蛋白作为肿瘤转移诊断标志物的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
CA2163032C (en) 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
US7258973B2 (en) * 1998-08-31 2007-08-21 Mayo Foundation For Medical Education & Research Method for detecting a differentially expressed sequence
US7169187B2 (en) 1999-12-22 2007-01-30 Ethicon, Inc. Biodegradable stent
AU2623201A (en) 1999-12-30 2001-07-16 Kam W Leong Controlled delivery of therapeutic agents by insertable medical devices
JP2003144176A (ja) 2000-12-27 2003-05-20 Inst Of Physical & Chemical Res 遺伝子多型の検出方法
US20030073096A1 (en) * 2001-02-09 2003-04-17 Pintex Pharmaceuticals, Inc. Pin1 as a marker for prostate cancer
AU784552B2 (en) 2001-03-02 2006-05-04 Cardinal Health 529, Llc Flexible stent
AU2002307466A1 (en) * 2001-04-20 2002-11-05 Millennium Pharmaceutical, Inc. Method for detecting breast cancer cells
AUPR969201A0 (en) 2001-12-20 2002-01-24 White, Geoffrey H. A device for use in intraluminal grafting
GB0213579D0 (en) 2002-06-13 2002-07-24 Astrazeneca Ab Methods
US20050163821A1 (en) 2002-08-02 2005-07-28 Hsing-Wen Sung Drug-eluting Biodegradable Stent and Delivery Means
US7153658B2 (en) 2002-09-19 2006-12-26 Applera Corporation Methods and compositions for detecting targets
US9078780B2 (en) 2003-11-08 2015-07-14 Cook Medical Technologies Llc Balloon flareable branch vessel prosthesis and method
US7468070B2 (en) 2004-01-23 2008-12-23 Boston Scientific Scimed, Inc. Stent delivery catheter
US7803178B2 (en) 2004-01-30 2010-09-28 Trivascular, Inc. Inflatable porous implants and methods for drug delivery

Also Published As

Publication number Publication date
WO2008086002A3 (en) 2008-10-23
EP2115173A2 (de) 2009-11-11
AU2008205330A1 (en) 2008-07-17
EP2115173B1 (de) 2011-09-21
US10094836B2 (en) 2018-10-09
US20100317726A1 (en) 2010-12-16
AU2008205330B2 (en) 2014-07-03
CA2674788A1 (en) 2008-07-17
WO2008086002A2 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
ATE525484T1 (de) Slco1b3-genotyp
CO7160023A2 (es) Métodos y aparatos para predecir riesgo de cáncer de próstata y volumen de glándula prostática
GB201021289D0 (en) Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
IL233098A (en) Cancer Detection and Prognosis Methods and Survival Probabilities and Biomarkers Based on Their Use
EP1922326A4 (de) Nützliche biomarker für die diagnose von prostatakrebs und methoden für ihre verwendung
AR066725A1 (es) Prediccion del pronostico para melanoma de cancer
WO2010018601A3 (en) Genetic variants predictive of cancer risk
NZ591613A (en) Polymorphic marker rs965513 for risk assessment of thyroid cancer
MX2009006378A (es) Biomarcadores para cancer.
IN2013CN01129A (de)
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
GB0720113D0 (en) Diagnostic, prognostic and predictive testing for cancer
MX2013010035A (es) Prediccion de neoplasmas neuroendocrinos gastroenteropancreaticos (gep-nens).
IL190870A0 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
ZA200803430B (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
EA201370063A1 (ru) Фосфолипидом рака
MX2010005960A (es) Biomarcadores de braf.
ZA200803516B (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
BR112012026536A2 (pt) sistemas e métodos para predizer deficiência gastrointestinal
MX2007013727A (es) Caracterizacion de cancer de prostata.
WO2007082144A3 (en) B7-h1 and survivin in cancer
IL205347A0 (en) Process for predicting the prognosis of squamous cell lung cancer
WO2011112845A3 (en) Methods and compositions related to a multi-methylation assay to predict patient outcome
EP1934603A4 (de) Biomarker für prostatakrebs
MX2009008247A (es) Biomarcadores de respuesta a la radiacion ionizante.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties